Clinical Trial Site Feasibility: Patient Accrual Velocity, Screen Failure Rates, and Enrollment Modeling
A quantitative statistical model for evaluating Phase II/III clinical site startup delays, protocol screen failures, and trial enrollment curves.
Clinical Trial Enrollment Modeler
Forecast site activation timelines, dropouts, and sample size power
Empirical Analysis & Findings
## Quantitative Feasibility in Clinical Trial Operations
Drug development sponsors invest over $1.5 billion per approved novel molecular entity. Accelerating time-to-market requires predicting patient recruitment curves using statistical non-homogeneous Poisson processes rather than static institutional estimates.
### 1. Accrual Velocity and Screen Failure Metrics by Therapeutic Area
| Therapeutic Area | Phase III Avg Duration | Screen Failure Rate | Monthly Accrual per Site | Site Startup Latency |
|:-----------------|:----------------------:|:-------------------:|:------------------------:|:--------------------:|
| Oncology (Targeted Biologics) | 36 Months | 42.5% | 0.45 Patients/mo | 7.2 Months |
| Cardiovascular (Outcomes) | 48 Months | 22.0% | 1.85 Patients/mo | 4.5 Months |
| Central Nervous System (CNS) | 42 Months | 48.0% | 0.65 Patients/mo | 6.8 Months |
| Rare Disease (Pediatric) | 60 Months | 64.0% | 0.18 Patients/mo | 9.4 Months |
Linked Entities in the Autonomous Knowledge Graph
Frequently Asked Questions
What percentage of clinical trial sites fail to meet their contracted patient recruitment target?
Industry cross-sectional studies reveal that 48% of global trial sites under-enroll, and 11% fail to enroll a single patient, inflating clinical development budgets.
How do restrictive inclusion/exclusion criteria impact trial duration?
Each added biomarker or laboratory threshold increases screen failure rates by 4% to 9%, necessitating more activated sites to sustain recruitment deadlines.
Related Research & Briefs
Hospital Revenue Cycle: DRG Reimbursement Modeling, Denial Rate Benchmarks, and Clean Claim Velocity
Analyzing Medicare MS-DRG case-mix indices, commercial payer initial denial rates, and administrative cost reduction across health systems.
Commercial General Liability: 2026 Underwriting Benchmarks and Loss-Ratio Modeling
A deep actuarial examination of commercial liability rate curves, contractual indemnity clauses, and secondary reinsurance retention limits.
SBA 7(a) Term Loan vs. Asset-Based Revolver: Weighted Cost of Capital Comparison
Mathematical cost-of-capital comparison between SBA 7(a) government-backed borrowing and bank asset-based revolving credit facilities.
Enterprise SaaS Procurement: Empirical Discount Curves by ACV Tier and Commitment Term
Regression analysis of 1,200 enterprise software contracts revealing true vendor negotiation boundaries across CRM, ERP, and observability platforms.